Evidence map›Paper›PMID 36261612›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2023

Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries.

Przemysław Holko, Paweł Kawalec, Magdalena Sajak-Szczerba, Luisa Avedano, Małgorzata Mossakowska

Abstract read
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Przemysław HolkoDepartment of Nutrition and Drug Research, Institute of Public Health, Jagiellonian University Medical College, Skawińska 8, 31-066, Krakow, Poland. p.holko@uj.edu.pl.ORCID http://orcid.org/0000-0002-6821-4078
Paweł KawalecDepartment of Nutrition and Drug Research, Institute of Public Health, Jagiellonian University Medical College, Skawińska 8, 31-066, Krakow, Poland.
Magdalena Sajak-SzczerbaEuropean Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.
Luisa AvedanoEuropean Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.
Małgorzata MossakowskaPolish Association Supporting People With Inflammatory Bowel Disease "J-Elita", Warsaw, Poland.

Funding

Uniwersytet Jagielloński Collegium Medicum N43/DBS/000099
6 · The paper itself

Abstract

backgroundThere is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, we compared patient costs of IBDs between 12 European countries.

methodsA questionnaire-based study was conducted among adult patients with IBD. Data on patient characteristics and out-of-pocket expenses were anonymously collected. Ordered logit regression models were used to analyse the responses provided by patients. The results were adjusted for confounders and multiplicity.

resultsThe questionnaires obtained from 3687 patients were analysed. Patients with comorbidities and active disease indicated higher out-of-pocket expenses than those without comorbidities and with disease in remission, respectively. Compared with other IBD, patients with ulcerative colitis indicated higher expenses on medications prescribed or recommended by physicians [odds ratio (OR) 1.99, 95% CI 1.48-2.67]. Expenses on dietary supplements, special diet or equipment, ostomy pouches, and transportation to a medical facility differed slightly between patients at different ages and were lower among men than among women (OR 0.71, 95% CI 0.54-0.93). The expenses differed significantly between countries. An adjusted mean patient cost per month varied from €77 (patient with Crohn disease in remission from Denmark) to €376 (patient with active ulcerative colitis from Romania). Compared with active disease, patients with IBD in remission had a lower out-of-pocket cost by 29-62% (€10-€22 monthly; p < 0.001).

conclusionsThe study revealed a high relevance of the out-of-pocket cost of IBD in the context of economic evaluation and a high variability of the cost between countries.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAdultFemaleHealth ExpendituresHumansMalePatient Reported Outcome MeasuresInflammatory bowel diseaseOut-of-pocket costsPatient-reported outcomes

Identifiers

PMID36261612
PMCPMC10406674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.